Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Glob Antimicrob Resist ; 17: 117-122, 2019 06.
Article in English | MEDLINE | ID: mdl-30553117

ABSTRACT

OBJECTIVES: The aim of this study was to assess the rate of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSIs) and the population structure of MRSA isolates recovered between 2000-2015 in a tertiary-care hospital in Athens, Greece. METHODS: Non-duplicate MRSA blood isolates recovered during the study period were examined. Antimicrobial susceptibility testing was performed by Kirby-Bauer and gradient strip methods. Carriage of PVL and mecA genes was examined by PCR. Genetic relatedness of the isolates was studied by SCCmec, spa and multilocus sequence typing. RESULTS: A total of 398 MRSA BSI cases were identified. A decreasing trend in incidence from 1.69/10 000 patient-days in 2000 to 1.39/10 000 patient-days in 2015 (P=0.038) and in prevalence from 64.7% to 36.4% (P=0.008), respectively, was observed, whereas the incidence of methicillin-susceptible S. aureus BSI increased. MRSA isolates exhibiting resistance to common antistaphylococcal agents (excluding glycopeptides and the newer antistaphylococcals) decreased from 84.8% in 2000 to 0% in 2011 and were progressively 'replaced' by more susceptible phenotypes. A strong association between antimicrobial resistance phenotype and molecular type was observed. The pandemic HA-MRSA clone ST239-III progressively declined in parallel with increasing isolation frequency of two clonal complexes (CCs): HA-MRSA CC5, with the majority of isolates belonging to ST5-II; and CA-MRSA CC80, represented mainly by ST80-IV-t044, PVL+. CONCLUSION: The decline in MRSA BSI rates observed in our institution was associated with changes in population structure of the organism. This decline may be related to biological properties of the prevailing MRSA clones.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacteremia/epidemiology , Methicillin-Resistant Staphylococcus aureus/drug effects , Staphylococcal Infections/epidemiology , Bacteremia/microbiology , Bacterial Typing Techniques , Community-Acquired Infections/epidemiology , Greece/epidemiology , Humans , Incidence , Methicillin-Resistant Staphylococcus aureus/classification , Microbial Sensitivity Tests , Multilocus Sequence Typing , Prevalence , Tertiary Care Centers , Time Factors
2.
Diagn Microbiol Infect Dis ; 88(4): 335-341, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28529091

ABSTRACT

Our aims were to identify factors associated with Pseudomonas aeruginosa (PA) bloodstream infection (BSI) in patients with hematological malignancies and evaluate the outcome of the affected patients. Consecutive patients with hematological malignancies who developed PA BSI were identified. Subsequently, two case-control studies were performed to evaluate the risk factors (i) for PA BSI and (ii) for carbapenem resistant (CR) PA BSI. Patients' outcome was evaluated at 28 days after the onset of bacteraemia. A total of 64 patients with PA BSI (45 caused by CS and 19 by CR organisms) and 128 without PA BSI were enrolled. Patients with rapidly fatal disease, steroid use, neutropenia or prior surgery were more likely to develop PA BSI, whereas patients with previous hospitalization and prior use of fluoroquinolones were more likely to develop CR PA BSI. The 28-day mortality rate was 35.9%. Severity of sepsis was the only independent predictor of adverse outcome.


Subject(s)
Bacteremia/drug therapy , Hematologic Neoplasms/microbiology , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/drug effects , Anti-Bacterial Agents/therapeutic use , Bacteremia/microbiology , Carbapenems/therapeutic use , Case-Control Studies , Drug Resistance, Bacterial/drug effects , Female , Fluoroquinolones/therapeutic use , Hospitalization , Humans , Male , Middle Aged , Pseudomonas Infections/microbiology , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...